Conflict Of Interest Rules Removed In Draft Of House User Fee Bill
This article was originally published in The Tan Sheet
Executive Summary
Reforms would end waiver caps for conflicts of interest, but whether they will solve the problems patient groups and others have with the advisory committee selection process is unclear. In a discussion draft, FDA could issue as many waivers of financial conflicts as it chose.
You may also be interested in...
Battle Lines Clear On Conflict Of Interest Policy In PDUFA Reauthorization
Commissioner Hamburg says the agency likely does not need legislation to improve its conflict of interest policy, but House members still say the system needs reform. Industry and patient advocate groups push for change, while consumer groups press FDA to stand firm.
Conflict Of Interest Reform: With FDA Undecided, Consumer Groups Give Their Pitch
FDA likes some rules in FDAAA and wants to continue discussion with Capitol Hill as changes are expected to be part of PDUFA legislation.
PDUFA Word Association: Consumer Advocates Complain About Lack Of "Safety" In Commitment Letter
FDA’s Oct. 24 public meeting on the renewal of its drug user fee program demonstrated just how strong a position the agency is in regarding the renewal of the Rx part of the “UFA” legislation – most of the complaints were semantic, quite literally.